Sbir phase I - topic 405 - project title: in vivo pharmacotyping of combination therapy in primary brain tumors firm fixed price - POP: 09/16/2020 - 06/15/2021
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91020C00021
- Awardee
-
Lodestone Biomedical Inc. UEI KSGGUNHRF8D5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $455,000
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · PHS20201 · Posted Jun 21, 2019
- Contract value 100% obligated
- $455,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 21 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Lebanon, NH 03766, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Exercise an Option | $55,000 | |
| Original award | $400,000 |
About this award
This is a firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Lodestone Biomedical LLC. The contract, valued at $455,000, is for research and development on in vivo pharmacotyping of combination therapy for primary brain tumors, under SBIR Topic 405. This is a total small business set-aside contract with a period of performance from September 16, 2020 to June 15, 2021, and a final completion date of September 15, 2021.
Quick answers
Who was awarded contract 75N91020C00021?
75N91020C00021 was awarded to Lodestone Biomedical Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2020.
How much is contract 75N91020C00021 worth?
The government has obligated $455,000 on 75N91020C00021.
Was contract 75N91020C00021 competed?
The extent of competition for 75N91020C00021 was full and open competition after exclusion of sources. The government received 21 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award